Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology

References

• Lo-Coco F, Avvisati G, Orlando SM et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the Phase III, prospective, randomized, intergroup APL0406 study by the Italian–German cooperative groups GIMEMA-SAL-AMLSG. ASH Annual Meeting Abstracts, 120(21), Abstract 6 (2012).
   Google Scholar
• Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol. 8(11), 1913–1921 (1990).
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, Frankel SR, Miller WH Jr et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324(20), 1385–1393 (1991).
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19(18), 3852–3860 (2001).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S et al; The European APL Group. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94(4), 1192–1200 (1999).
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337(15), 1021–1028 (1997).
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martín G, González M et al.; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103(4), 1237–1243 (2004).
   PubMed Web of Science ®Google Scholar
• Adès L, Sanz MA, Chevret S et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French–Belgian–Swiss and PETHEMA results. Blood 111(3), 1078–1084 (2008).
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19), 3751–3757 (2010).
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG et al.; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120(8), 1570–80; quiz 1752 (2012).
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 27(4), 504–510 (2009).
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118(5), 1248–1254 (2011).
   PubMed Web of Science ®Google Scholar
• Rahme R, Thomas X, Recher C et al. Early deaths (ED) in acute promyelocytic leukemia (APL) in France: a retrospective multicenter study in 355 patients (pts). ASH Annual Meeting Abstracts 120(21), Abstract 890 (2012).
   Google Scholar
• Othus M, Kantarjian HM, Petersdorf S et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given ‘intensive’ induction regimens: a report from the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). ASH Annual Meeting Abstracts 120(21), Abstract 129 (2012).
   Google Scholar
• Lehmann S, Lazarevic V, Horstedt A-S et al. Poor outcome in secondary acute myeloid leukemia (AML): a first report from the population-based Swedish Acute Leukemia Registry. ASH Annual Meeting Abstracts 120(21), Abstract 130 (2012).
   Google Scholar
• Beaumont M, Sanz M, Carli PM et al. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 21(11), 2123–2137 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J. Clin. Oncol. 28(4), 549–555 (2010).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, McMullin MF et al. A randomised comparison of clofarabine versus low dose ara-C as first line treatment for older patients with AML. ASH Annual Meeting Abstracts 120(21), Abstract 889 (2012).
   Google Scholar
• Burnett AK, Russell NH, Kell J et al. A Comparison of daunorubicin/ara-C (DA) versus daunorubicin/clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 trial. ASH Annual Meeting Abstracts 120(21), Abstract 892 (2012).
   Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24), 5089–5102 (2010).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Perl AE, Dombret H et al. Final Results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. ASH Annual Meeting Abstracts 120(21), Abstract 48 (2012).
   Google Scholar
• Levis MJ, Perl AE, Dombret H et al. Final Results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. ASH Annual Meeting Abstracts 120(21), Abstract 673 (2012).
   Google Scholar
• Rollig C, Muller-Tidow C, Huttmann A et al. Sorafenib versus placebo in addition to standard therapy in adult patients ≥60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled SORAML trial. ASH Annual Meeting Abstracts 120(21), Abstract 144 (2012).
   Google Scholar
• Smith CC, Lasater E, Mccreery M et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutants. ASH Annual Meeting Abstracts 120(21), Abstract 141 (2012).
   Google Scholar
• Andreeff M, Zeng Z, Kelly MA et al. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/G-CSF/sorafenib: results from a Phase I trial in relapsed/refractory AML patients. ASH Annual Meeting Abstracts 120(21), Abstract 142 (2012).
   Google Scholar